Pharmaceutical Supply Chain Security: Managing Risk Across Packaging and Distribution
Most pharmaceutical manufacturers have mature quality control systems inside the facility — raw materials are tested, processes are monitored, and batches are reviewed before release.
Packaging and distribution rely on different control mechanisms.
These stages are where product identity is established and where supply chain risks are most likely to surface — including counterfeit, diverted, or tampered products entering legitimate channels.
Managing these risks requires controls that extend beyond manufacturing systems, including serialization, authentication, and traceability across trading partners.
This guide outlines those controls, why they matter, and how to build them into a coherent pharmaceutical supply chain security program.
Key Takeaways
- Packaging defines product identity — errors introduced at the unit level persist through the entire supply chain and shape every downstream outcome
- DSCSA compliance depends on data exchange — reliable transmission of serialization data across trading partners determines whether traceability works in practice
- Authentication enables downstream verification — product legitimacy can only be confirmed in distribution through controls applied at packaging
- Counterfeit and diversion risk persists — products enter legitimate supply chains at points where identity cannot be independently verified
- Returns verification controls re-entry risk — saleable returns processes determine whether products of uncertain origin re-enter the supply chain
- Contract manufacturing increases system complexity — serialization and traceability must function across multiple partners and data environments
Let's get started
Covectra offers brand protection and supply chain integrity. Contact us to learn how.
The Three Control Layers of Pharmaceutical Supply Chain Security
Pharmaceutical supply chain security is structured across three distinct control layers. Each addresses a different category of risk across packaging and distribution.
- Identity: Established at the packaging line
Serialization and aggregation define the identity of each product unit. This layer determines how products are recognized and referenced throughout the supply chain. - Traceability: Maintained across trading partners
Traceability systems record how products move between organizations. DSCSA and EPCIS define how that data is exchanged and used during investigations. - Verification: Applied in distribution
Authentication technologies confirm that the physical product matches its assigned identity. This layer addresses counterfeit and diversion risk at the point of dispensing or inspection.
Where gaps occur
Supply chain failures typically occur when one of these layers is missing or disconnected:
- Identity without traceability limits visibility across the supply chain
- Traceability without verification allows counterfeit products to carry valid data
- Verification without identity lacks a reliable system of record
Manufacturers implement these layers differently based on product risk, distribution models, and regulatory requirements.
Pharmaceutical Packaging as a Quality Control Stage
Identity layer: Packaging is where unit-level product identity is established through serialization and aggregation.
Ask most pharmaceutical operations teams where quality control lives, and the answer centers on the manufacturing floor — blend monitoring, equipment qualification, batch release. Packaging is typically treated as a finishing step.
Packaging is also where pharmaceutical supply chain security is either established or compromised. Every downstream control — traceability, verification, and recall precision — depends on what happens at the packaging line.
What gets established at the packaging line
Three elements are defined at packaging and cannot be corrected downstream:
- Serialized identifiers — the unique codes assigned to each saleable unit that enable DSCSA traceability
- Authentication features — overt, covert, and digital elements that support product verification at any downstream point
- Aggregation data — the records linking units to cases and cases to pallets, forming the structure of supply chain traceability
Errors at any of these points do not stay at packaging, but surface later as compliance failures, recall complications, or authentication breakdowns that are expensive and time-consuming to unwind.
The scale of packaging-related risk
Labeling and packaging errors account for approximately 19% of FDA drug recalls over a 10-year period.
That places packaging among the top drivers of recalls, alongside impurities and control issues — and reflects a category of risk that manufacturing quality systems are not designed to detect once products leave the line.
Serialized identifiers define unit-level identity
Serialized identifiers define a product unit’s identity for its entire commercial lifecycle. Once a serial number is assigned and commissioned into a traceability system, it becomes the unit’s record of origin, movement, and authenticity.
If the identifier is misassigned, unreadable, or not recorded correctly, the unit’s identity in the supply chain is compromised from that point forward.
Authentication features enable downstream verification
Authentication features determine whether a product can be verified at any point in the supply chain — by a pharmacist, a customs inspector, or a patient before dispensing.
Features applied at the packaging line — visible security elements, embedded covert markers, or digital verification links — are what make downstream verification possible. Without them, product authenticity cannot be confirmed after distribution.
Aggregation data enables traceability at scale
Aggregation data connects serialized units to the cases and pallets they move through. That structure allows regulators, logistics partners, and manufacturers to trace a product’s path through the supply chain.
Gaps in aggregation data are gaps in traceability. During investigations or recalls, those gaps slow response time and expand the scope of affected product.
Why automated inspection does not close these gaps
Vision systems and inspection tools are standard on pharmaceutical packaging lines. They detect many issues, but they do not address the full set of risks.
Three limitations persist:
- Line speed compresses inspection time
At high throughput, each unit receives only a fraction of a second of inspection - Similar packaging designs increase misread risk
Nearly identical artwork across SKUs creates known failure conditions - Calibration drift creates silent failures
Slight misalignment produces false negatives — errors that pass inspection and reach distribution
Automated inspection is a necessary layer of packaging quality control. It does not address the data integrity required for serialization, authentication, and traceability to function reliably.
DSCSA Track and Trace Requirements: What Pharmaceutical Manufacturers Need to Implement
Traceability layer: DSCSA defines how product movement is recorded and exchanged across trading partners.
The Drug Supply Chain Security Act is the federal framework for pharmaceutical supply chain security in the United States. A decade into implementation, core requirements are in effect, but execution still varies across systems and trading partners.
FDA has taken a phased approach to enforcement, with compliance timelines extending through November 2026 for certain dispensers. As a result, trading partners are not operating at the same level of readiness.
Even fully compliant manufacturers may exchange data with partners that lack complete serialization, aggregation, or verification capabilities. These gaps affect how reliably traceability data can be used during investigations and product verification — and they do not always originate with the manufacturer.
What DSCSA requires
- Serialization at the saleable unit level
A unique product identifier applied to the package sold to the pharmacy (e.g., bottle, carton) - Standardized data elements
Each identifier encodes:- National Drug Code (NDC)
- Serial number
- Lot number
- Expiration date
- Electronic traceability
Systems must exchange transaction data with trading partners - Verification and investigation capability
Manufacturers must be able to verify, trace, and investigate products across the supply chain on request
What DSCSA does not require
- Unit-dose serialization
Tracking individual tablets, capsules, or pouches is not a federal mandate
Manufacturers building serialization programs should align infrastructure with regulatory requirements, not extend it based on assumptions about future mandates.
How EPCIS-based traceability works
EPCIS is the data standard that enables DSCSA traceability across organizations. It captures four types of supply chain events:
- Commissioning — a serial number is assigned at the packaging line
- Shipping — the unit leaves a facility
- Receiving — the unit arrives at the next trading partner
- Decommissioning — the unit is removed from commerce
Each event creates a record of product movement and establishes accountability across the supply chain.
Key distinction: DSCSA establishes traceability. It does not verify that the physical product matches the data record.
The role of aggregation in traceability
Serialization at the unit level is only part of the system. Aggregation links units to cases and cases to pallets, enabling traceability at scale.
Without accurate aggregation data:
- Shipment contents cannot be reconstructed quickly
- Investigations require manual reconciliation
- Targeted recalls expand beyond affected units
Saleable returns and verification
Returned product introduces one of the highest-risk scenarios in pharmaceutical distribution.
Before a returned unit can re-enter inventory, DSCSA requires verification against the original transaction record. This is typically handled through a Verification Router Service (VRS), which confirms whether the product identifier is valid and eligible for resale.
Why verification is a supply chain security control
A returned product that has been tampered with, counterfeited, or diverted can appear identical to a legitimate return.
Without verification:
- Products of uncertain origin re-enter the supply chain
- Compliance exposure increases under DSCSA requirements
- No audit trail exists if a product later causes a safety event
Verification is not an administrative step. It is a control point for product integrity.
Operational challenges with returns verification
Manual verification processes brings delays and inconsistencies:
- Phone-based or spreadsheet-driven lookups slow response time
- Inconsistent execution creates compliance gaps
- Lack of system integration limits auditability
Cloud-based serialization repositories enable automated VRS queries, making verification immediate, consistent, and auditable.
Pharmaceutical Anti-Counterfeiting Controls in the Distribution Channel
Verification layer: Authentication technologies confirm that the physical product matches its assigned identity.
Serialization establishes a product’s identity at the packaging line and tracks it through the supply chain. Authentication addresses a different problem: confirming that the physical product matches that identity.
A counterfeit product can carry a copied serial number. A diverted product can have a legitimate serial number assigned to the wrong market. Serialization alone does not resolve either scenario. Authentication does.
The scale of counterfeit and diversion risk
Global law enforcement agencies uncovered more than 6,400 incidents of pharmaceutical counterfeiting (excluding non-commercial size seizures of illegal pharmaceuticals), illegal diversion, and theft across 136 countries in 2024, according to the Pharmaceutical Security Institute.
That figure reflects detected incidents. The total volume of counterfeit and diverted product moving through global supply chains is higher.
How counterfeit products enter legitimate channels
- Second-tier and informal distributors operating outside primary wholesale networks
- Free trade zones where products can be relabeled or repackaged with limited oversight
- Online pharmacies and direct-to-consumer channels with minimal verification
- Returns fraud — counterfeit products submitted as legitimate returns and reintroduced into inventory
Where authentication extends beyond serialization
Serialization verifies the data record. Authentication verifies the physical product.
A sophisticated counterfeit can replicate a serial number. It cannot replicate a physical security feature designed to be non-reproducible.
Three layers of pharmaceutical authentication
Each layer addresses a different point of failure:
- Overt features
Visible to inspectors, pharmacists, and patients without specialized tools. These features support rapid screening and create immediate deterrence. - Covert features
Embedded within packaging materials and detectable only with the appropriate verification method. Designed for use by brand owners, regulators, and customs authorities. Because they are not visible, they are more difficult to identify and replicate. - Digital verification
Links a physical feature to a serialized data record. When scanned, the product returns a verification result tied to its history, connecting the physical object to its traceability data.
Together, these layers create redundancy. A failure in one does not compromise the entire system.
Let's get started
Covectra offers brand protection and supply chain integrity. Contact us to learn how.
Drug Supply Chain Security Beyond the Primary Distribution Tier
Most pharmaceutical distribution security programs focus on primary wholesalers. That coverage does not extend to the full set of channels where risk is introduced.
Counterfeit and diverted products most often enter through:
- Secondary distributors
- Gray market intermediaries
- Online and non-traditional channels
Diversion and counterfeiting: distinct risks
- Counterfeiting — products that are falsified, with incorrect or missing active ingredients
- Diversion — legitimate products sold outside authorized channels (wrong market, pricing tier, or geography)
Both create supply chain security failures and require controls that extend beyond the manufacturing facility.
What authentication enables at the point of dispensing
Authentication at the point of dispensing allows pharmacists or patients to verify a product before use, without specialized equipment.
This changes two things:
- Prevents compromised product from reaching patients
- Generates data that reveals supply chain patterns
Scan events provide:
- Geographic verification data
- Volume anomalies across regions
- Indicators of diversion or unauthorized distribution
Authentication functions as both a verification mechanism and a source of supply chain intelligence.
How Contract Manufacturers Manage Pharmaceutical Serialization Compliance Across Multiple Brand Owners
Cross-layer complexity: Contract manufacturing environments must support identity and traceability across multiple systems.
The global pharmaceutical contract manufacturing market was valued at $96.5 billion in 2024.
Contract manufacturing now represents a significant share of pharmaceutical production.
That scale introduces a specific supply chain security challenge. Contract manufacturers must maintain DSCSA serialization compliance for multiple brand owners simultaneously, each operating different traceability systems with different data requirements.
The interoperability challenge
Brand owners operate Level 5 serialization repositories — cloud-based systems that store and manage serialization data. These repositories vary in:
- Data formats
- Communication protocols
- Connectivity requirements
A contract manufacturer typically operates a single serialization environment that must connect to all of them.
Without the right infrastructure, two options emerge:
- Maintain separate systems for each customer
- Require brand owners to change their systems
Neither is operationally viable.
How serialization gateways enable multi-partner compliance
Serialization gateway technology manages the translation layer between systems. It converts data formats and communication protocols to match each trading partner’s requirements.
This allows:
- A single serialization environment
- Compliant data exchange across multiple brand owner repositories
- No system replacement on either side
Shared responsibility for compliance
DSCSA places serialization and traceability obligations on both parties:
- Contract manufacturers
- Commission serial numbers
- Transmit event data accurately
- Brand owners
- Maintain complete and accurate repository records
- Reflect what was commissioned and aggregated at the contract site
Gaps in that connection create compliance risk for both parties.
Unit-dose serialization in high-risk product categories
Some pharmaceutical brands choose to serialize below the saleable unit level, tracking individual doses rather than packages.
This is not a DSCSA requirement but a brand-driven decision used for specific high-risk product categories where diversion risk justifies additional control.
Example:
- Opioid addiction therapy medications packaged in individual foil pouches
- Each pouch can carry a serial number
- Dose-level tracking supports tighter control over diversion risk
For most pharmaceutical products, saleable unit serialization meets both regulatory requirements and supply chain security objectives.
Pharmaceutical Supply Chain Security: Closing the Gaps Across Packaging and Distribution
Packaging and distribution are where pharmaceutical supply chain security is established — and where it breaks down. The controls that matter — serialization, authentication, traceability, and returns verification — are applied at these stages. The gaps that lead to recalls, compliance failures, and counterfeit products reaching patients originate here as well.
Manufacturers that manage these risks effectively treat packaging as the starting point for supply chain security.
- Serialized identifiers are applied accurately and connected to traceability systems
- Authentication features are embedded at the unit level
- Aggregation data is captured completely and maintained across systems
- Verification infrastructure is in place to confirm product legitimacy at each downstream handoff
Where supply chain security gaps remain
- Serialization without precision
Systems meet DSCSA requirements but lack the data integrity needed for targeted investigations and recalls - Authentication limited to primary distribution
Controls do not extend to second-tier distributors or the point of dispensing - Disconnected contract manufacturing environments
Serialization data does not flow reliably between contract sites and brand owner repositories - Manual or inconsistent returns verification
Processes introduce delays, reduce auditability, and increase risk of reintroducing compromised product
How Covectra supports pharmaceutical supply chain security across every layer
Covectra works with pharmaceutical manufacturers and contract organizations to build these connections. With more than 4 billion serial numbers issued worldwide, Covectra provides integrated serialization, authentication, and traceability systems that support pharmaceutical supply chain security from the packaging line through final distribution.
AuthentiTrack manages serialization and track-and-trace at scale, from line-level commissioning through cloud-based EPCIS data exchange.
StellaGuard applies overt, covert, and digital authentication at the packaging line, with consumer-facing verification that extends security to the point of dispensing.
ControlTrack supports adherence monitoring and unit-level serialization beyond the saleable package for manufacturers of high-risk medications requiring dose-level control.
If your team is evaluating gaps in packaging, serialization, or distribution controls, request a call to review your current supply chain security architecture and identify where integration is needed.
Let's get started
Covectra offers brand protection and supply chain integrity. Contact us to learn how.
FAQ: Pharmaceutical Supply Chain Security
DSCSA requires serialization at the saleable unit level — the package sold to the pharmacy. Each unit must carry a product identifier with NDC, serial number, lot, and expiration date. Unit-dose serialization is not required.
Learn more about Covectra's pharmaceutical solutions:
- Pharmaceutical industry overview
- AuthentiTrack serialization and track-and-trace platform
- StellaGuard authentication label technology
- ControlTrack medication adherence and dose-level serialization
- Pharmaceutical serialization services
- Services overview
- Our work
Further reading:
- DSCSA Compliance 2025: What Pharma Companies Need to Know Now
- Staying Ahead of the DSCSA Curve
- Should I Serialize or Authenticate My Packaging?
- Many Happy Returns
- Serialization ROI
- Vaccine Manufacturers Are Outsourcing Packaging Serialization — What About You?
- Connecting Enterprise Serialization
- Taking the Mystery Out of Counterfeiting
- The Opioid Paradox